Paradigm Biopharmaceuticals
www.paradigmbiopharma.comParadigm’s (ASX: PAR) immediate commercial focus is the repurposing of Pentosan Polysulfate Sodium (PPS) for the treatment of Osteoarthritis (OA). This is a global unmet need and we have advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain, and regeneration, PPS has genuine disease-modifying potential.
Read more
Paradigm’s (ASX: PAR) immediate commercial focus is the repurposing of Pentosan Polysulfate Sodium (PPS) for the treatment of Osteoarthritis (OA). This is a global unmet need and we have advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain, and regeneration, PPS has genuine disease-modifying potential.
Read more
Country
City (Headquarters)
Melbourne
Industry
Employees
11-50
Founded
2014
Estimated Revenue
$1 to $1,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Medical Officer
Email ****** @****.comPhone (***) ****-****Chief Scientific Officer
Email ****** @****.comPhone (***) ****-****Chief Executive Officer
Email ****** @****.comPhone (***) ****-****Snr Clinical Affairs Director
Email ****** @****.comPhone (***) ****-****
Technologies
(33)
Reach decision makers at Paradigm Biopharmaceuticals
Free credits every month!
Paradigm Biopharmaceuticals FAQ
Melbourne, Australia
Biotechnology Research
